Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$9.11 USD
-0.02 (-0.22%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $9.10 -0.01 (-0.11%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DTIL 9.11 -0.02(-0.22%)
Will DTIL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
Other News for DTIL
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
Precision BioSciences chief medical officer Alan List to retire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
Precision BioSciences Secures Funds, Bolsters Oncology Partnership